Alphatec Holdings Management
Management criteria checks 2/4
Alphatec Holdings' CEO is Pat Miles, appointed in Mar 2018, has a tenure of 8.25 years. total yearly compensation is $10.26M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 3.2% of the company’s shares, worth $40.73M. The average tenure of the management team and the board of directors is 7.2 years and 19.3 years respectively.
Key information
Pat Miles
Chief executive officer
US$10.3m
Total compensation
| CEO salary percentage | 7.43% |
| CEO tenure | 8.3yrs |
| CEO ownership | 3.2% |
| Management average tenure | 7.2yrs |
| Board average tenure | 19.3yrs |
Recent management updates
Recent updates
Narrative Update • Jun 05
ATEC: New Bank Facility And 2026 Outlook Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $20.00 to $11.00, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Alphatec reported Q1 2026 total revenue of $192 million, with surgical revenue growth of 17% and total revenue growth of 14%, according to recent earnings coverage (source: Alphatec Reports Strong Q1 2026 Growth and Secures New Bank Facility).Seeking Alpha • May 19
Alphatec - Slower Growth Seems Priced In Here
Summary Alphatec Holdings shares have dropped two-thirds YTD, now trading at just over 2x sales, reflecting sharply decelerating growth and persistent losses. Q1 2026 revenue grew only 14% to $192.1M, prompting a slight full-year sales guidance cut; adjusted EBITDA margins improved but remain heavily adjusted. Despite a $466M net debt load and ongoing dilution, Alphatec demonstrates real operating leverage, with manageable losses and a credible path toward profitability. Slowing topline growth and elusive margins temper enthusiasm, but current valuation appears compelling versus medtech peers, making Alphatec a speculative yet interesting play. Read the full article on Seeking Alpha
Narrative Update • May 14
ATEC: 2026 Surgical Revenue Focus Will Support Future Upside Potential
Analysts have reduced their price target for Alphatec Holdings from about $24.62 to about $17.33 as they adjust assumptions for discount rate, revenue growth, profit margin, and future P/E in their models. What's in the News Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, targeting total revenue of about $882 million, with surgical revenue expected to grow 17% as part of that outlook (corporate guidance).
Narrative Update • Apr 29
ATEC: 2026 Revenue Guidance Will Drive Constructive Upside Case
Analysts have kept their $28.00 price target for Alphatec Holdings unchanged, noting that only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E offset one another in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, indicating no change to its previously communicated outlook.Narrative Update • Apr 15
ATEC: 2026 Revenue Outlook Will Support Bullish Return Potential
Analysts have kept their $28.00 price target on Alphatec Holdings unchanged, citing updated assumptions that include a higher discount rate, stronger modeled revenue and profit margins, and a lower future P/E multiple that together balance out in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, maintaining its outlook for that period.Narrative Update • Mar 31
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $22.00 to $20.00, citing updated assumptions for revenue growth, profit margins and future P/E that together point to a more measured long term outlook for the shares. What's in the News Reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% above full year 2025 revenue (Corporate Guidance).Narrative Update • Mar 17
ATEC: 2026 Revenue Outlook And Spine Biologics Partnership Will Support Upside
Analysts have left their $28.00 price target for Alphatec Holdings unchanged, citing a slightly higher assumed discount rate, a moderated revenue growth outlook, stronger projected profit margins, and a lower future P/E as key factors supporting the steady valuation. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million.Narrative Update • Mar 03
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside Potential
Analysts have adjusted their Alphatec Holdings target to $24.62, reflecting updated assumptions that combine slightly lower expected revenue growth with higher projected profit margins and a reduced future P/E multiple, while applying a somewhat higher discount rate. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% higher than full year 2025 revenue (company guidance).Narrative Update • Feb 17
ATEC: 2026 Revenue Guidance And Spine Biologics Deal Will Drive Upside
Analysts have maintained their $28.00 price target for Alphatec Holdings, citing steady model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions as reasons to hold their prior valuation line. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately $890m for the year ended December 31, 2026 (Corporate Guidance).Narrative Update • Feb 03
ATEC: Partnership And 2026 Revenue Outlook Will Reshape Spine Biologics Opportunity
Analysts have raised their fair value estimate for Alphatec Holdings from $23.00 to $28.00, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe better reflect the company’s current outlook. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of about $890 million compared to full year 2025 (Corporate Guidance).Narrative Update • Jan 20
ATEC: Higher 2026 Revenue Outlook And New Partnership Will Support Upside
Analysts have lifted their price target on Alphatec Holdings from US$14.00 to US$22.00, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E as the key drivers of the change. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately US$890 million for the year.Analysis Article • Jan 06
Are Alphatec Holdings, Inc. (NASDAQ:ATEC) Investors Paying Above The Intrinsic Value?
Key Insights Alphatec Holdings' estimated fair value is US$17.32 based on 2 Stage Free Cash Flow to Equity Alphatec...Narrative Update • Jan 06
ATEC: Higher 2025 Revenue Guidance Will Support A More Optimistic Outlook
Analysts have inched their price target for Alphatec Holdings higher to about $24.62 from $24.00, reflecting small tweaks to fair value estimates, discount rate assumptions, and a slightly higher future P/E multiple in their models. What's in the News Alphatec Holdings raised earnings guidance for the fiscal year ending December 31, 2025, indicating updated expectations for the business outlook.Narrative Update • Dec 14
ATEC: Revenue Will Reach 760 Million As Outlook Remains Favorable
Analysts have modestly raised their price target on Alphatec Holdings by 0.25 dollars to 24.00 dollars, reflecting slightly higher long term valuation multiples despite only marginal tweaks to growth, margin and discount rate assumptions. What's in the News Alphatec Holdings raised its earnings guidance for fiscal 2025, now expecting total revenue to increase 24 percent to 760 million dollars, compared with the prior outlook of 742 million dollars (company guidance filing) Valuation Changes Fair Value Estimate has risen slightly to 24.00 dollars from 23.75 dollars, reflecting a modest uplift in long term valuation.Narrative Update • Nov 29
ATEC: Revenue Will Reach $760 Million As Guidance Increases And Outlook Remains Steady
Analysts have maintained their fair value price target for Alphatec Holdings at $23.75, citing only minor adjustments to underlying financial assumptions along with a steady outlook for growth and profitability. What's in the News Alphatec Holdings raised its earnings guidance for the fiscal year ending December 31, 2025, reflecting increased confidence in the company's outlook (Key Developments).Narrative Update • Nov 15
ATEC: Total Revenue Will Reach $760 Million Next Year
Narrative Update on Alphatec Holdings: Analyst Price Target Revision Analysts have increased their price target for Alphatec Holdings from $20.54 to $23.75. This change reflects revised financial assumptions and updated expectations for the company’s future performance.Narrative Update • Nov 01
ATEC: Improved Margins And Revenue Projections Will Shape Future Performance
Analysts have raised their price target for Alphatec Holdings from $19.41 to $20.54 per share, citing improved profit margin forecasts and stronger projected revenue growth as key reasons for the increased valuation. What's in the News Alphatec Holdings, Inc.Analysis Article • Oct 05
Not Many Are Piling Into Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Yet
With a median price-to-sales (or "P/S") ratio of close to 2.8x in the Medical Equipment industry in the United States...Narrative Update • Sep 20
Expanding Spine Care And Integrated Tech Will Drive Future Opportunities
The slight increase in Alphatec Holdings’ future P/E ratio reflects higher growth expectations, which has contributed to a modest rise in its consensus analyst price target from $18.95 to $19.41. What's in the News Raised full-year 2025 revenue guidance to $742 million, up 21% year-over-year, surpassing previous forecast of $734 million.Analysis Article • Jul 28
Are Investors Undervaluing Alphatec Holdings, Inc. (NASDAQ:ATEC) By 43%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Alphatec Holdings fair value estimate is US$19.10 Current...Analysis Article • Jul 09
Should You Investigate Alphatec Holdings, Inc. (NASDAQ:ATEC) At US$11.60?
While Alphatec Holdings, Inc. ( NASDAQ:ATEC ) might not have the largest market cap around , it led the NASDAQGS...New Narrative • May 27
Robotics And Minimally Invasive Techniques Will Expand Spine Care
Innovative spine solutions and expanding minimally invasive offerings position Alphatec for sustained revenue growth and margin expansion amid rising global spine care demand.Analysis Article • May 11
Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 25% But Many Are Still Ignoring The Company
Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shares have had a really impressive month, gaining 25% after a shaky period...Analysis Article • Apr 20
Alphatec Holdings (NASDAQ:ATEC) Is Making Moderate Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Mar 01
Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates
Shareholders of Alphatec Holdings, Inc. ( NASDAQ:ATEC ) will be pleased this week, given that the stock price is up 18...Analysis Article • Jan 18
Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 31% But Many Are Still Ignoring The Company
Despite an already strong run, Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shares have been powering on, with a gain of 31...Analysis Article • Dec 19
Here's Why Alphatec Holdings (NASDAQ:ATEC) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Dec 03
Alphatec: A Big Recovery
Summary Alphatec, a medtech company focused on spine solutions, has faced investor concerns due to continued losses, cash burn, and increasing debt despite revenue growth. Shares plunged 40% after Q2 earnings, but have recovered following the release of the third quarter results following management's comments about positive cash flow in Q4. Management's optimistic outlook is further backed up by significant improvement in EBITDA seen in 2025. Despite the positive reaction, Alphatec still needs to prove its ability to reduce debt and avoid further dilution while executing its growth plans. Read the full article on Seeking AlphaAnalysis Article • Nov 01
Alphatec Holdings, Inc. (NASDAQ:ATEC) Soars 50% But It's A Story Of Risk Vs Reward
Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shareholders would be excited to see that the share price has had a great...Analysis Article • Aug 29
Positive Sentiment Still Eludes Alphatec Holdings, Inc. (NASDAQ:ATEC) Following 38% Share Price Slump
The Alphatec Holdings, Inc. ( NASDAQ:ATEC ) share price has fared very poorly over the last month, falling by a...Analysis Article • Aug 28
We Think Alphatec Holdings (NASDAQ:ATEC) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$125m |
| Dec 31 2025 | US$10m | US$762k | -US$143m |
| Sep 30 2025 | n/a | n/a | -US$155m |
| Jun 30 2025 | n/a | n/a | -US$166m |
| Mar 31 2025 | n/a | n/a | -US$166m |
| Dec 31 2024 | US$6m | US$757k | -US$162m |
| Sep 30 2024 | n/a | n/a | -US$178m |
| Jun 30 2024 | n/a | n/a | -US$181m |
| Mar 31 2024 | n/a | n/a | -US$192m |
| Dec 31 2023 | US$9m | US$713k | -US$187m |
| Sep 30 2023 | n/a | n/a | -US$172m |
| Jun 30 2023 | n/a | n/a | -US$166m |
| Mar 31 2023 | n/a | n/a | -US$152m |
| Dec 31 2022 | US$6m | US$700k | -US$151m |
| Sep 30 2022 | n/a | n/a | -US$157m |
| Jun 30 2022 | n/a | n/a | -US$163m |
| Mar 31 2022 | n/a | n/a | -US$164m |
| Dec 31 2021 | US$5m | US$683k | -US$143m |
| Sep 30 2021 | n/a | n/a | -US$131m |
| Jun 30 2021 | n/a | n/a | -US$104m |
| Mar 31 2021 | n/a | n/a | -US$81m |
| Dec 31 2020 | US$5m | US$436k | -US$79m |
| Sep 30 2020 | n/a | n/a | -US$69m |
| Jun 30 2020 | n/a | n/a | -US$68m |
| Mar 31 2020 | n/a | n/a | -US$65m |
| Dec 31 2019 | US$8m | US$550k | -US$57m |
Compensation vs Market: Pat's total compensation ($USD10.26M) is above average for companies of similar size in the US market ($USD5.29M).
Compensation vs Earnings: Pat's compensation has increased whilst the company is unprofitable.
CEO
Pat Miles (60 yo)
8.3yrs
Tenure
US$10,260,507
Compensation
Mr. Patrick S. Miles, also known as Pat, is Venture Partner at ullis Health Investors of Florida LLC since November 2025. He is Chairman & Chief Executive Officer of Alphatec Spine, Inc. Mr. Miles was Exec...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 8.3yrs | US$10.26m | 3.2% $ 40.7m | |
| Executive VP & CFO | 5.2yrs | US$3.83m | 0.13% $ 1.7m | |
| Chief Operating Officer | 2.4yrs | US$5.27m | 0.19% $ 2.4m | |
| Executive Vice President of Sales | 7.2yrs | US$3.95m | 0.055% $ 694.5k | |
| Executive Vice President of People & Culture | 9.8yrs | US$6.32m | 0.77% $ 9.8m | |
| VP of Finance and Investor Relations & Controller | 7.8yrs | no data | no data | |
| General Counsel & Corporate Secretary | 2.9yrs | no data | 0.17% $ 2.2m | |
| Senior Vice President of Marketing | 3.6yrs | no data | no data | |
| Executive Vice President of Commercial Operations | 9.5yrs | no data | no data | |
| Chief Medical Officer | 8.3yrs | no data | no data | |
| Senior Vice President of Global Imaging Solutions | 4.4yrs | no data | no data |
7.2yrs
Average Tenure
52yo
Average Age
Experienced Management: ATEC's management team is seasoned and experienced (7.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 8.7yrs | US$10.26m | 3.2% $ 40.7m | |
| Independent Lead Director | 21.3yrs | US$242.49k | 0.79% $ 10.1m | |
| Chairman of Scientific Advisory Board | 20.7yrs | US$42.42k | no data | |
| Independent Director | 7yrs | US$249.99k | 0.035% $ 443.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 19.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 19yrs | no data | no data | |
| Member of Scientific Advisory Board | 19.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
19.3yrs
Average Tenure
66.5yo
Average Age
Experienced Board: ATEC's board of directors are seasoned and experienced ( 19.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/15 09:03 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alphatec Holdings, Inc. is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Miksic | Barclays |
| Caitlin Cronin | Canaccord Genuity |
| Tao Levy | Deutsche Bank |